# SUNNIFORECAST (NCT03075423)

> Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab
- Indication: previously untreated advanced non-clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03075423
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Goethe University
- Conditions: Metastatic Renal Cell Carcinoma
- Interventions: Ipilimumab plus nivolumab; Standard Therapy
- Enrollment: 316
- Primary outcome: Overall survival rate at 12 months (OS12) (landmark)

## Indexed commentary on SUNNIFORECAST so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 69 posts on X
- 34 YouTube videos
- 22 podcast episodes
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sunniforecast-nct03075423

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03075423", "email": "<work email>"}; the inbox owner confirms by the emailed link.